National Nanotechnology Initiative’s Post

#RecentlyPublished: A short sequence in the SARS-CoV-2 spike protein, also in vaccines, produces an autoantibody that recognizes human proteins, possibly unc-80, potentially causing autoimmune disorders in humans. Read now: https://lnkd.in/gJPYfRWg Research Article: "In Silico and In Vitro Evaluation of the Molecular Mimicry of the SARS-CoV-2 Spike Protein by Common Short Constituent Sequences (cSCSs) in the Human Proteome: Toward Safer Epitope Design for Vaccine Development", by Yuya Mizuno, Wataru Nakasone, Morikazu Nakamura and Joji M. Otaki. Keywords: SARS-CoV-2; #spike; short constituent #sequence; human #proteome; #epitope; #autoantibody; #autoimmune disease; vaccine development; molecular mimicry; immunological tolerance.

New financing and clinical trial for RSV/hMOV bivalent vaccine Vicebio has announced a $100 million Series B financing, which will be used to develop next-generation vaccines for respiratory viruses.  The development will utilise Vicebio’s Molecular Clamp technology, discovered at The University of Queensland. The technology stabilises viral glycoproteins in their highly immunogenic ‘prefusion’ conformation, crucial for eliciting strong protective immune responses.  This approach enables the production of highly effective vaccines that are easy to manufacture and will be available in ready-to-use prefilled syringes. The technology is applicable to a wide range of viruses including Respiratory Syncytial Virus (RSV), Human Metapneumovirus (hMPV), Parainfluenza virus, Influenza and Coronaviruses, as confirmed by promising preclinical and clinical studies. https://lnkd.in/eUh5zMGa #Vaccine #ClinicalTrials #DrugDevelopment

🦠🌍 Remarkable progress in COVID vaccine development and implementation over the past four years! Researchers from academia, industry, government, and NGOs have collaborated to accelerate vaccine development, leading to Emergency Use Authorizations for 64 vaccines globally. Various platforms, including mRNA, DNA, viral vectors, and recombinant proteins, have been utilized, targeting different components of the virus. Despite reduced global COVID-19 deaths by up to 95%, new infections continue to pose challenges due to emerging variants. The fight against COVID-19 remains a significant public health priority. #COVID19 #VaccineDevelopment #PublicHealth 🩺💉

About the relevance of Bioinformatics in vaccine development, a group of scientists identified CD4+ and CD8+ T cell epitopes from Chikungunya antigens using in-silico approaches. These findings have contributed to characterize and support the efficacy of an important vaccine in a phase II clinical trial. The study underscores the crucial role of in silico methods in advancing vaccine development against various infectious diseases worldwide. #Bioinformatics #vaccines #efficacy If interested, the research article can be found here: https://lnkd.in/exe9CZip

"Our new study, 'Identification of potential antigenic proteins and epitopes for the development of a monkeypox virus vaccine: an in silico approach,' has been published in Molecular Diversity! We conducted in silico analyses to contribute to the development of an effective vaccine against the monkeypox virus. Special thanks to our mentors and contributors for their invaluable support throughout this study. Check out our work here: https://lnkd.in/dgxzPCHp #Monkeypox #VaccineDevelopment #InSilico #Bioinformatics #MolecularBiology #Immunology #VirusResearch #MolecularDiversity #AcademicResearch #PublicHealth #AntigenicProteins #ScientificPublication

🌟 Exciting News from Desert King! 🌟 We are thrilled to share groundbreaking research published in The Lancet Microbe on a new SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with the Army Liposomal Formulation containing QS-21 (ALFQ)! This Phase 1, randomized, double-blind, placebo-controlled clinical trial, led by the Walter Reed Army Institute of Research, demonstrates the vaccine's impressive safety and immunogenicity. 🔬 Key Highlights: ✅ The vaccine, co-formulated with the Army Liposomal Formulation (ALFQ) containing monophosphoryl lipid A and QS-21, showed protective efficacy in animal models and now in human trials. ✅ Participants received either 25 μg or 50 μg of the vaccine, with strong neutralizing antibody responses and T-cell activation observed. ✅ The study confirms the vaccine's robust and durable immune response against a broad range of SARS-CoV-2 variants, including challenging omicron subvariants. At Desert King, we are proud of QS-21’s pivotal role as part of the ALFQ adjuvant system in enhancing vaccine efficacy. Our commitment to quality and innovation drives us to support such critical advancements in global health. Read more about this exciting development and join us in celebrating this milestone in vaccine research! 🔗 Explore More: https://shorturl.at/R9TTo 🌐 Follow Us: Stay updated on our journey by following our LinkedIn page. #Vaccine #Innovation #Immunology #DesertKing #WRAIR #QS21 #ALFQ #Quillaja #Saponins #GlobalHealth

#hiringalert Tenure-track Junior Professor Chair, Université Jean Monnet: The Chair will play a crucial role in the international collaborations "Global Pandemic Preparedness" and "100 Days Mission" to swiftly create vaccine strategies against new pathogens. The aim of the PREVENT project is to devise innovative vaccine approaches for emerging infections, particularly those affecting the respiratory and digestive systems, to proactively prevent future pandemics. Within GIMAP, the Chair will be a significant contributor, focusing on various aspects of research including fundamental, clinical, and practical applications. Additionally, it will be part of an international initiative (IPCEI Santé - Sanofi) dedicated to enhancing mRNA vaccines for respiratory diseases, utilizing human challenge models to expedite the vaccine development process, specifically targeting influenza and coronaviruses. https://buff.ly/3Q0sbyv

MIT scientists have introduced a groundbreaking approach to enhance vaccine efficacy by leveraging a new type of nanoparticle. Their study reveals that metal-organic particles possess dual functionality: they can serve as carriers for vaccine delivery and also act as adjuvants to stimulate a robust immune response even at lower doses. Engineers at MIT have specifically engineered a nanoparticle vaccine utilizing a metal-organic framework known as ZIF-8. This innovative vaccine design incorporates the SARS-CoV-2 receptor binding protein and an adjuvant named Gdq , promising to bolster vaccine effectiveness against infectious diseases like COVID-19. https://lnkd.in/e68JYPmd

🔬 My New Article on a Novel SARS-CoV-2 Poly-Epitope Phage-Based Vaccine Candidate is Now Published! 🦠 This research explored an innovative approach to vaccine development by combining multiple epitopes from SARS-CoV-2 proteins to stimulate a stronger immune response. Using phage display technology, we designed a cost-effective and stable vaccine candidate capable of triggering both humoral and cellular immunity. 📌 Highlights: ✅ Effective Immune Response: This vaccine effectively activated humoral and cellular immunity in animal models. ✅ Advantages of Phages: Phages offer stability, low cost, and strong immunogenic properties without posing infection risks for humans. ✅ Potential for Broader Protection: This vaccine may offer resilience against SARS-CoV-2 variants by targeting multiple epitopes. I hope this achievement contributes to developing next-generation vaccines capable of safeguarding our communities against viral threats. Many thanks to my colleagues for their invaluable support and collaboration! For more information go to: https://lnkd.in/daT9v3-S very thanks to Mahmood Fadaie, Elham Ghafouri, and Zohre Amirkhani

MY QUESTION, if it is considered that the N protein of COVID-19 is weakly susceptible to mutation, and S1 is highly susceptible (34x) to mutate so far, while it has antigenic similarities with over 20 types of human tissue, causing numerous immunological complications, why was no mRNA vaccine made for N protein? At the end of the pandemic, he states that the right choice was the Chinese vaccine SINOFARM. CONCLUSION:the variability of the N protein is less than the variability of the S protein. To date, only seven VoC/VoI mutations have occurred in the N protein, compared to 34 mutations in the S protein, indicating that the N protein is more conserved. Most of the key residual mutations of SARS-CoV-2 also occur in the S protein, which can evade the immune system and reduce the immunogenicity and efficacy of vaccines, representing a significant obstacle to the effectiveness of current prevention and control strategies [ 40 ]. Therefore, it is particularly important to find a target to address SARS-CoV-2 mutations in the autoimmune process of patients with SARS-CoV-2, and HLA alleles may be helpful to find such a target. https://lnkd.in/ePsJ-cbY